EUVIMEDEUVIMED entdecken
Crossref

Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy

Jake R Thompson iD, Julia Lai-Kwon iD, Rachael L Morton iD, Alexander D Guminski iD, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu iD, Michael P Brown iD, Alexander M Menzies iD, Grant A McArthur iD, Serigne N Lo iD, Georgina V Long iD und 1 weitere

Immunotherapy · 2023

DOI: 10.2217/imt-2022-0262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Jake R Thompson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Melanoma Institute Australia, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab-nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan-Meier method was used to determine median time to first deterioration.

Results

Asymptomatic MBM patients treated with ipilimumab-nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement.

Conclusion

MBM patients treated with either ipilimumab-nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 (ClinicalTrials.gov). Historically, people whose melanoma had spread to the brain (known as brain metastases) lived only 4–6 months after diagnosis, with less than 15% alive at 12 months. However, the development of immunotherapies such as nivolumab and ipilimumab to treat advanced melanoma has resulted in more than 50% of patients being alive 5 years after diagnosis. With the effectiveness of these immunotherapies demonstrated in clinical trials, we wanted to examine the impact of these treatments on the health-related quality of life of people with melanoma brain metastases. Using data from a clinical trial evaluating the effectiveness of immunotherapies in people diagnosed with melanoma brain metastases, this study investigated the impact of nivolumab and nivolumab combined with ipilimumab on quality of life. We found that neither nivolumab alone nor nivolumab combined with ipilimumab had a negative effect on quality of life. In summary, this study provides further support for the use of these immunotherapies as first-line treatment for melanoma brain metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaBrain NeoplasmsHumansNivolumabIpilimumabQuality of LifeImmunotherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

HRQoLbrain metastasesipilimumabmelanomanivolumab

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia.
  • National Health and Medical Research Council Clinical Trials Center, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2050, Australia.
  • Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia.
  • Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia.
  • Faculty of Medicine, University of Queensland, Brisbane, Queensland, 4072, Australia.

ORCID-Profile: Jake R Thompson, Julia Lai-Kwon, Rachael L Morton, Alexander D Guminski, Shahneen Sandhu, Michael P Brown, Alexander M Menzies, Grant A McArthur, Serigne N Lo, Georgina V Long, Iris Bartula

Förderung

  • Melanoma Institute Australia
  • Bristol Myers Squibb

Zitieren

APA

Thompson, J. R., Lai-Kwon, J., Morton, R. L., Guminski, A. D., Gonzalez, M., Atkinson, V., Sandhu, S., Brown, M. P., Menzies, A. M., McArthur, G. A., Lo, S. N., Long, G. V., & Bartula, I. (2023). Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy. Immunotherapy. https://doi.org/10.2217/imt-2022-0262

Vancouver

Thompson JR, Lai-Kwon J, Morton RL, Guminski AD, Gonzalez M, Atkinson V, et al. Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy. Immunotherapy. 2023. doi:10.2217/imt-2022-0262

BibTeX
@article{Thompson2023,
  author = {Thompson, Jake R and Lai-Kwon, Julia and Morton, Rachael L and Guminski, Alexander D and Gonzalez, Maria and Atkinson, Victoria and Sandhu, Shahneen and Brown, Michael P and Menzies, Alexander M and McArthur, Grant A and Lo, Serigne N and Long, Georgina V and Bartula, Iris},
  title = {Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2022-0262}
}
Kostenlos starten →